Workshop report from the National Institutes of Health Taskforce on the Research Needs of Eosinophil-Associated Diseases (TREAD)
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Background Eosinophils are blood cells that are often found in high numbers in the tissues of allergic conditions and helminthic parasite infections. The pathophysiological roles that eosinophils may serve in other human ‘eosinophil-associated’ diseases remain obscure. Objective NIH Institutes and the Office of Disease Prevention assembled an international taskforce of clinical and basic scientists with the charge to propose and prioritize unmet research needs in eosinophil-associated diseases. Methods The taskforce used an organ system approach to dissect out the different and common themes of eosinophil cell involvement in these diseases. In early 2012, a draft document was circulated for review. The document was amended and the prioritizations were set at a NIH-organized workshop in June 2012. Results The taskforce identified significant research needs. These needs cross disease entities but some are disease-specific. There are substantial shortcomings to the various preclinical animal models, as well as significant gaps in our epidemiologic, pathophysiologic, diagnostic, prognostic and therapeutic knowledge. The taskforce recognized that recent efforts by patient advocacy groups have played instrumental roles in improving the identification and characterization of these disorders. However, communication amongst the eosinophil interested communities, e.g., governmental funding and regulatory agencies, and industry and clinician scientists need to be more comprehensive. Conclusions Significant efforts are required to address our knowledge gaps in order to improve the outcomes of eosinophil-associated diseases. NIH Institutes, other federal agencies, lay organizations and the pharmaceutical industry should consider the taskforce’s recommendations in their future research activities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Furuta, G. T., Liacouras, C. A., Collins, M. H., Gupta, S. K., Justinich, C., Putnam, P. E., Bonis, P., Hassall, E., Straumann, A., & Rothenberg, M. E. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.08.017 · Cited by 1,673
Self-citationMepolizumab, a humanized anti–IL-5 mAb, as a treatment option for severe nasal polyposis
Gevaert, P., Van Bruaene, N., Cattaert, T., Van Steen, K., Van Zele, T., Acke, F., De Ruyck, N., Blomme, K., Sousa, A. R., Marshall, R. P., et al. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.07.056 · Cited by 629
Noth, I., Strek, M. E., & Leff, A. R. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12518-4 · Cited by 527
Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome
Kim, S., Marigowda, G., Oren, E., Israel, E., & Wechsler, M. E. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.03.028 · Cited by 280
Self-citation
Cited by
Eosinophils: changing perspectives in health and disease
Rosenberg, H. F., Dyer, K. D., & Foster, P. S. (2013) · Nature Reviews Immunology · doi:10.1038/nri3341 · Cited by 989
Revisiting the systemic vasculitis in eosinophilic granulomatosis with polyangiitis (Churg-Strauss)
Cottin, V., Bel, E., Bottero, P., Dalhoff, K., Humbert, M., Lazor, R., Sinico, R. A., Sivasothy, P., Wechsler, M. E., Groh, M., et al. (2017) · Autoimmunity Reviews · doi:10.1016/j.autrev.2016.09.018 · Cited by 175
Self-citationActivation states of blood eosinophils in asthma
Johansson, M. W. (2014) · Clinical & Experimental Allergy · doi:10.1111/cea.12292 · Cited by 158
Eosinophil-derived IL-4 drives progression of myocarditis to inflammatory dilated cardiomyopathy
Diny, N. L., Baldeviano, G. C., Talor, M. V., Barin, J. G., Ong, S., Bedja, D., Hays, A. G., Gilotra, N. A., Coppens, I., Rose, N. R., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20161702 · Cited by 99
“The National Institutes of Health workshop study on the Research Needs of Eosinophil-Associated Diseases points out an urgent need for preclinical models and a mechanistic understanding of eosinophil-mediated cardiac damage (Bochner et al., 2012).”
BackgroundLong-term clinical outcomes of high-dose mepolizumab treatment for hypereosinophilic syndrome
Kuang, F. L., Fay, M. P., Ware, J., Wetzler, L., Holland-Thomas, N., Brown, T., Ortega, H., Steinfeld, J., Khoury, P., & Klion, A. D. (2018) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2018.04.033 · Cited by 94
Self-citationCheung, C. C., Constantine, M., Ahmadi, A., Shiau, C., & Chen, L. Y. C. (2017) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2017.04.002 · Cited by 78
Diny, N. L., Hou, X., Barin, J. G., Chen, G., Talor, M. V., Schaub, J., Russell, S. D., Klingel, K., Rose, N. R., & Čiháková, D. (2016) · European Journal of Immunology · doi:10.1002/eji.201646557 · Cited by 70
Hypereosinophilia causes progressive cardiac pathologies in mice
Diny, N. L., Wood, M. K., Won, T., Talor, M. V., Lukban, C., Bedja, D., Wang, N., Kalinoski, H., Daoud, A., Talbot, C. C., et al. (2023) · iScience · doi:10.1016/j.isci.2023.107990 · Cited by 7
“Nevertheless, current therapies do not eliminatemorbidity and there is an ongoing need for the development of preclinical models andmechanistic understanding of the molecular pathology.(10,11) Eosinophils are multi-potent effector cells that can modulate immune responses and tissue remodeling but also cause tissue dam…”
Metadata
- Authors
- Bochner, B. S., Book, W., Busse, W. W., Butterfield, J., Furuta, G. T., Gleich, G. J., Klion, A. D., Lee, J. J., Leiferman, K. M., Minnicozzi, M., Moqbel, R., Rothenberg, M. E., Schwartz, L. B., Simon, H.-U., Wechsler, M. E., & Weller, P. F.
- Venue
- Journal of Allergy and Clinical Immunology
- Publisher
- Elsevier BV
- Published
- 2012-09
- Volume
- 130
- Issue
- 3
- Pages
- 587-596
- ISSN
- 0091-6749 (ISSN-L)
- OpenAlex
- W2024967704
- Cited by
- 55
- References
- 4
- FWCI
- 2.83
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.